Who is the CEO of Wonbiogen?

According to the DART company overview, Wonbiogen's representative director is 김원일 (name as registered in Korean). The company was founded on 2018-09-03.

Where is Wonbiogen listed?

Wonbiogen trades on the Korea Exchange KOSDAQ market under the ticker 307280. Its fiscal year ends in December.

Does Wonbiogen pay a dividend?

Yes. For fiscal 2025, Wonbiogen paid a cash dividend of ₩140 per common share, a 2.2% yield as stated in its annual report, with a payout ratio of 15.3%. The prior year's dividend was ₩20.

Does Wonbiogen have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Op. margin 20%+ (operating margin of 20% or more on quarterly revenue of at least ₩5bn); Dividend grower (dividend per share raised three years in a row). These are factual flags, not investment advice.

Which companies are in the same industry as Wonbiogen?

Under the Korean Standard Industrial Classification recorded on DART, Wonbiogen is grouped with 31 other listed companies in medical supplies. The most covered in Korean news over the past 30 days are HLB, PharmaResearch and HLB Panagene.

Wonbiogen KRX:307280KOSDAQ

원바이오젠 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days0

DART filings, 7 days0

Articles tracked2since Sep 11

In Q2 2026, Wonbiogen reported revenue of ₩9.9bn, up 18.3% year on year, and operating profit of ₩2.8bn. Wonbiogen (원바이오젠) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 18 with 1 article.

Filing signals Op. margin 20%+ Dividend grower Screener

Wonbiogen quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩9.9bn	+18.3%	₩2.8bn margin 28.0%	₩2.8bn
Q1 2026	₩9.3bn	+12.4%	₩2.1bn margin 22.8%	₩1.9bn
Q4 2025 derived	₩9.4bn	+10.1%	₩2.1bn margin 22.4%	₩1.5bn
Q3 2025	₩9.2bn	+34.3%	₩2.4bn margin 26.0%	₩2.2bn
Q2 2025	₩8.4bn	+5.0%	₩1.9bn margin 22.5%	₩1.4bn
Q1 2025	₩8.3bn	+16.7%	₩1.5bn margin 18.6%	₩1.3bn
Q4 2024 derived	₩8.5bn	+15.4%	₩1.5bn margin 17.6%	₩1.3bn
Q3 2024	₩6.9bn	-1.3%	₩1.7bn margin 24.5%	₩1.3bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Wonbiogen top stories 2 weeks, by number of outlets

1
원바이오젠, 한국생체재료학회 추계학술대회서 ‘메디솝’ 피부 케어 기술력 선봬
1 outlets · 1 articlesFirst report Sep 22 14:44 바이오타임즈
2
원바이오젠, 구미혜당학교 견학… 지역사회와 함께하는 현장체험 프로그램 운영
1 outlets · 1 articlesFirst report Sep 18 11:12 서울신문

Latest Wonbiogen news Korean headlines

Sep 2214:44

원바이오젠, 한국생체재료학회 추계학술대회서 ‘메디솝’ 피부 케어 기술력 선봬
바이오타임즈
Sep 1811:12

원바이오젠, 구미혜당학교 견학… 지역사회와 함께하는 현장체험 프로그램 운영
서울신문

Articles per day 2 weeks

118

122

Company profile

CEO: 김원일
Industry: Medical supplies
Founded: 2018-09-03
Fiscal year-end: December
Head office: 경상북도 구미시
Website: wonbiogen.co.kr
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Wonbiogen dividends annual report

Korea dividend rankings

Year	Per share	Yield	Payout
FY2025	₩140	2.2%	15.3%
FY2024	₩20	1.8%	12.5%
FY2023	₩10	1.3%	12.9%

Raised 3 years in a row

Same industry Medical supplies

All in industry

Company	Latest quarter op. profit	Articles 30d
HLB	−₩22.5bn	92
PharmaResearch	₩66.5bn	82
HLB Panagene	−₩158m	24
SCL Science	₩406m	22
Gencurix	−₩702m	19
Hans Biomed	–	14
Rokit Healthcare	−₩13.5bn	14
ISU Abxis	₩479m	10

Compare Wonbiogen side by side with these companies

Wonbiogen DART filings

No filings yet.

Mentioned alongside 2 weeks

No co-mentioned companies yet.

Wonbiogen FAQ

Who is the CEO of Wonbiogen?: According to the DART company overview, Wonbiogen's representative director is 김원일 (name as registered in Korean). The company was founded on 2018-09-03.
Where is Wonbiogen listed?: Wonbiogen trades on the Korea Exchange KOSDAQ market under the ticker 307280. Its fiscal year ends in December.
What were Wonbiogen's latest quarterly results?: In Q2 2026, Wonbiogen reported revenue of ₩9.9bn, up 18.3% year on year, and operating profit of ₩2.8bn. Figures come from reports filed on DART.
Does Wonbiogen pay a dividend?: Yes. For fiscal 2025, Wonbiogen paid a cash dividend of ₩140 per common share, a 2.2% yield as stated in its annual report, with a payout ratio of 15.3%. The prior year's dividend was ₩20.
Does Wonbiogen have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Op. margin 20%+ (operating margin of 20% or more on quarterly revenue of at least ₩5bn); Dividend grower (dividend per share raised three years in a row). These are factual flags, not investment advice.
Which companies are in the same industry as Wonbiogen?: Under the Korean Standard Industrial Classification recorded on DART, Wonbiogen is grouped with 31 other listed companies in medical supplies. The most covered in Korean news over the past 30 days are HLB, PharmaResearch and HLB Panagene.